Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts

Neoplasia (United States)

Volumn 15, Issue 4, 2013, Pages 409-420

  Schauer, Isaiah Gregory ^a   Zhang, Jing ^a,b   Xing, Zhen ^a   Guo, Xiaoqing ^a   Mercado Uribe, Imelda ^a   Sood, Anil K ^a   Huang, Peng ^a   Liu, Jinsong ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN P53; SUPPRESSOR OF CYTOKINE SIGNALING 1; SYNAPTOTAGMIN I; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; VASCULOTROPIN;

ADULT; AGED; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; DISEASE FREE SURVIVAL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TISSUE MICROARRAY; UPREGULATION; WESTERN BLOTTING;

EID: 84875684114     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121228     Document Type: Article

References (48)

1. Kenny PA, Lee GY, and BissellMJ (2007). Targeting the tumor microenvironment. Front Biosci 12, 3468-3474.
2. Bissell MJ and RadiskyD(2001). Putting tumours in context. Nat Rev Cancer 1(1), 46-54.
3. Kalluri R and Zeisberg M (2006). Fibroblasts in cancer. Nat Rev Cancer 6(5), 392-401.
4. Tlsty TD and Hein PW (2001). Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 11(1), 54-59.
5. Bhowmick NA, Neilson EG, and Moses HL (2004). Stromal fibroblasts in cancer initiation and progression. Nature 432(7015), 332-337.
6. Orimo A and Weinberg RA (2006). Stromal fibroblasts in cancer: a novel tumorpromoting cell type. Cell Cycle 5(15), 1597-1601.
7. Ostman A and Augsten M (2009). Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev 19(1), 67-73.
8. Raman D, Baugher PJ, Thu YM, and Richmond A (2007). Role of chemokines in tumor growth. Cancer Lett 256(2), 137-165.
9. Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60(5), 277-300.
10. Network CGAR (2011). Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609-615.
11. Aylon Y and Oren M (2011). New plays in the p53 theater. Curr Opin Genet Dev 21(1), 86-92.
12. Kamp DW, Shacter E, and Weitzman SA (2011). Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park) 25(5), 400-410, 413.
13. Bar J, Feniger-Barish R, Lukashchuk N, Shaham H, Moskovits N, Goldfinger N, Simansky D, Perlman M, Papa M, Yosepovich A, et al. (2009). Cancer cells suppress p53 in adjacent fibroblasts. Oncogene 28(6), 933-936.
14. OlivierM, Petitjean A, Marcel V, Pétré A, MounawarM, Plymoth A, de Fromentel CC, and Hainaut P (2009). Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther 16(1), 1-12.
15. Ness RB and Cottreau C (1999). Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91(17), 1459-1467.
16. Hanahan D and Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell 144(5), 646-674.
17. Grivennikov SI, Greten FR, and Karin M (2010). Immunity, inflammation, and cancer. Cell 140(6), 883-899.
18. Freedman RS, Deavers M, Liu J, and Wang E (2004). Peritoneal inflammation-a microenvironment for epithelial ovarian cancer (EOC). J Transl Med 2(1), 23.
19. Wang X, Wang E, Kavanagh JJ, and Freedman RS (2005). Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med 3, 25.
20. Karin M (2006). Nuclear factor-κB in cancer development and progression. Nature 441(7092), 431-436.
21. Karin M (2009). NF-κB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1(5), a000141.
22. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, and Aggarwal BB (2011). NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene 30(14), 1615-1630.
23. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, et al. (2004). A genetically defined model for human ovarian cancer. Cancer Res 64(5), 1655-1663.
24. Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA, Mercado-Uribe I, and Liu J (2006). The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci USA 103(44), 16472-16477.
25. Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, and Liu J (2006). Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 106(9), 1925-1932.
26. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, and Liu J (2009). ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 22(6), 817-823.
27. Yang G, Thompson JA, Fang B, and Liu J (2003). Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. Oncogene 22(36), 5694-5701.
28. Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC Jr, Zhou C, and Liu J (2007). Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis 28(1), 174-182.
29. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, and Haegeman G (2003). Transcriptional activation of the NF-κB p65 subunit by mitogen-and stress-activated protein kinase-1 (MSK1). EMBO J 22(6), 1313-1324.
30. Calabrese V, Mallette FA, Deschênes-Simard X, Ramanathan S, Gagnon J, Moores A, Ilangumaran S, and Ferbeyre G (2009). SOCS1 links cytokine signaling to p53 and senescence. Mol Cell 36(5), 754-767.
31. Dvorak HF (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315(26), 1650-1659.
32. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, et al. (1998). Tumor induction of VEGF promoter activity in stromal cells. Cell 94(6), 715-725.
33. Schauer IG and Rowley DR (2011). The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation 82(4-5), 200-210.
34. Schauer IG, Sood AK, Mok S, and Liu J (2011). Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 13(5), 393-405.
35. Bogenrieder T and Herlyn M (2003). Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22(42), 6524-6536.
36. Campbell IG, Qiu W, Polyak K, and Haviv I (2008). Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15), 1634-1635; author reply 1636.
37. Dudley AC, Shih SC, Cliffe AR, Hida K, and Klagsbrun M (2008). Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br J Cancer 99(1), 118-125.
38. Hawsawi NM, Ghebeh H, Hendrayani SF, Tulbah A, Al-Eid M, Al-Tweigeri T, Ajarim D, Alaiya A, Dermime S, and Aboussekhra A (2008). Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res 68(8), 2717-2725.
39. Hill R, Song Y, Cardiff RD, and Van Dyke T (2005). Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123(6), 1001-1011.
40. Kiaris H, Chatzistamou I, Trimis G, Frangou-Plemmenou M, Pafiti-Kondi A, and Kalofoutis A (2005). Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res 65(5), 1627-1630.
41. Komarova EA, Diatchenko L, RokhlinOW, Hill JE, Wang ZJ, Krivokrysenko VI, Feinstein E, and Gudkov AV (1998). Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene 17(9), 1089-1096.
42. Addadi Y, Moskovits N, Granot D, Lozano G, Carmi Y, Apte RN, Neeman M, and Oren M (2010). p53 Status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 70(23), 9650-9658.
43. Dey A, Tergaonkar V, and Lane DP (2008). Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways. Nat Rev Drug Discov 7(12), 1031-1040.
44. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, et al. (2005). Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κBdependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 102(48), 17448-17453.
45. Wadgaonkar R, Phelps KM, Haque Z, Williams AJ, Silverman ES, and Collins T (1999). CREB-binding protein is a nuclear integrator of nuclear factor-κB and p53 signaling. J Biol Chem 274(4), 1879-1882.
46. Rocha S, Garrett MD, Campbell KJ, Schumm K, and Perkins ND (2005). Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J 24(6), 1157-1169.
47. McTavish N, Copeland LA, Saville MK, Perkins ND, and Spruce BA (2007). Proenkephalin assists stress-activated apoptosis through transcriptional repression of NF-κB-and p53-regulated gene targets. Cell Death Differ 14(9), 1700-1710.
48. Niu J, Chang Z, Peng B, Xia Q, Lu W, Huang P, Tsao MS, and Chiao PJ (2007). Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-κB transcription factors. J Biol Chem 282(9), 6001-6011.